|
Study reveals inaccuracies in studies of cancer treatment
April 21, 2008Certain biases may exist in observational studies that compare outcomes of different cancer therapies, making the results questionable. That is the conclusion of a new study published in the June 1, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society. The research suggests that observational studies should include more thorough information and should be better designed to minimize inaccuracies.
Clinical trials are considered the gold standard for demonstrating the effectiveness of new treatments for cancer, but observational studies, which do not involve randomization but where available data are nonetheless analyzed to make treatment comparisons, have also been used to provide information on how well patients respond to particular drugs. Many investigators perform these types of studies by analyzing data from the Surveillance, Epidemiology and End Results (SEER) Tumor Registry, a national population-based cancer registry that collects cancer-related information.
To determine the accuracy of observational studies on cancer treatments, Dr. Sharon H. Giordano of the University of Texas MD Anderson Cancer Center in Houston and her colleagues compared the effectiveness of different cancer therapies in terms of prolonging survival in patients, using data from the SEER registry. They presented several examples, including re-analyses of previously published data. In all cases, they came up with improbable results, indicating how easy it is to generate questionable results when conducting an observational study.
In their first analysis, the researchers looked at data on a hormone therapy called androgen deprivation in men with stage III prostate cancer. Randomized clinical trials have shown that androgen deprivation can improve survival in these patients. When the investigators analyzed data from the SEER registry of more than 5,000 men, they found that men treated with androgen deprivation actually had a higher risk of death from prostate cancer than men who did not receive the therapy.
Dr. Giordano and her team next re-analyzed data from a previously published study of more than 43,000 men with localized prostate cancer who were treated compared with men who were not treated. Like the original study, the researchers' analysis revealed that men who were treated for prostate cancer experienced lower mortality rates. However, they also found that in many cases, the cause of death was due to something other than prostate cancer, such as diabetes or pneumonia.
Finally, the investigators re-analyzed data from a previously published study on the effects of fluorouracil-based chemotherapy for colon cancer. They came to the same conclusion as the original research study-that chemotherapy for node positive colon cancer is associated with improved survival. However, they found that the link between the treatment and survival was strongest for non-cancer deaths, which presumably are not related.
The authors attributed the improbable results found in their three analyses to selection biases when patients are treated. For example, selection bias occurs when patients with poorer prognoses are more likely to receive a more efficacious drug, or when patients with better underlying health are more likely to receive a more toxic treatment because they are more likely to tolerate it.
The authors concluded that their findings "suggest that the results of observational studies of treatment outcomes should be viewed with caution." They recommended that analyses of observational data should at a minimum attempt to segregate patient outcomes into those that could possibly be due to the treatments vs. those that could not. Many observational studies on cancer treatments only report death rates from all causes and do not specify cancer-related deaths.
American Cancer Society
In their first analysis, the researchers looked at data on a hormone therapy called androgen deprivation in men with stage III prostate cancer. Randomized clinical trials have shown that androgen deprivation can improve survival in these patients. When the investigators analyzed data from the SEER registry of more than 5,000 men, they found that men treated with androgen deprivation actually had a higher risk of death from prostate cancer than men who did not receive the therapy.
Dr. Giordano and her team next re-analyzed data from a previously published study of more than 43,000 men with localized prostate cancer who were treated compared with men who were not treated. Like the original study, the researchers' analysis revealed that men who were treated for prostate cancer experienced lower mortality rates. However, they also found that in many cases, the cause of death was due to something other than prostate cancer, such as diabetes or pneumonia.
Finally, the investigators re-analyzed data from a previously published study on the effects of fluorouracil-based chemotherapy for colon cancer. They came to the same conclusion as the original research study-that chemotherapy for node positive colon cancer is associated with improved survival. However, they found that the link between the treatment and survival was strongest for non-cancer deaths, which presumably are not related.
The authors attributed the improbable results found in their three analyses to selection biases when patients are treated. For example, selection bias occurs when patients with poorer prognoses are more likely to receive a more efficacious drug, or when patients with better underlying health are more likely to receive a more toxic treatment because they are more likely to tolerate it.
The authors concluded that their findings "suggest that the results of observational studies of treatment outcomes should be viewed with caution." They recommended that analyses of observational data should at a minimum attempt to segregate patient outcomes into those that could possibly be due to the treatments vs. those that could not. Many observational studies on cancer treatments only report death rates from all causes and do not specify cancer-related deaths.
American Cancer Society
Prostate Cancer News and Current Prostate Cancer Events RSSElevated biomarkers predict risk for prostate cancer recurrence
A simple blood test screening for a panel of biomarkers can accurately predict whether a patient who has had prostate cancer surgery will have a recurrence or spread of the disease.
Researchers identify promising cancer drug target in prostate tumors
Scientists at Dana-Farber Cancer Institute report they have blocked the development of prostate tumors in cancer-prone mice by knocking out a molecular unit they describe as a "powerhouse" that drives runaway cell growth.
Certain anticancer agents could be harmful to patients with heart disease
A set of promising new anticancer agents could have unforeseen risks in individuals with heart disease, suggests research at Washington University School of Medicine in St. Louis.
Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis
Cancer patients with low socioeconomic status (SES) have more advanced cancers at diagnosis, receive less aggressive treatment, and have a higher risk of dying in the five years following cancer diagnosis, according to a new study.
UT Southwestern urologists identify seven biomarkers that may help pinpoint prostate cancer recurrence
A simple blood test may help doctors better predict whether prostate cancer will recur or spread in patients who have undergone surgery for the disease, UT Southwestern Medical Center researchers have found.
Radiation therapy prolongs life in men with recurrent prostate cancer
Men whose tumors recur after prostate cancer surgery are three times more likely to survive their disease long term if they undergo radiotherapy within two years of the recurrence.
OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer
In a multi-site study, Oregon Health & Science University Cancer Institute researchers have found that a drug called Ipilimumab, also known as MDX-010, works to stimulate the body's own immune system to fight prostate cancer. The drug was found to be effective in study participants with a serious type of prostate cancer - one where the tumor has spread and was resistant to hormonal treatment and, in some cases, also to chemotherapy.
OHSU Cancer Institute researchers find novel chemo drug helps treat prostate cancer
Men with a certain type of prostate cancer have been shown to respond to a new chemotherapy drug, Sagopilone, plus prednisone in an international trial led by Oregon Health & Science University Cancer Institute researchers.
How advanced prostate cancer becomes resistant to androgen-deprivation therapy
For the past 70 years the treatment of choice for advanced, metastatic prostate cancer has been androgen-deprivation therapy.
Certain form of tomatoes could be key to prostate cancer prevention
New cancer research from the University of Missouri suggests that eating a certain form of tomato product could be the key to unlocking the prostate cancer-fighting potential of the tomato.
More Prostate Cancer News Articles
 | Dr. Patrick Walsh's Guide to Surviving Prostate Cancer, Second Edition by Patrick C. Walsh, Janet Farrar Worthington |
 | The Vitamin D Cure by James Dowd, Diane Stafford |
 | Prostate Health in 90 Days by Larry Clapp |
 | You Can Beat Prostate Cancer by Robert J. Marckini |
 | A Primer on Prostate Cancer: The Empowered Patient's Guide by Stephen Strum, Donna L. Pogliano |
 | The Natural Prostate Cure by Roger Mason |
 | Prostate And Cancer: A Family Guide To Diagnosis, Treatment And Survival (3rd Edition) by Sheldon Marks |
 | Dr. Patrick Walsh's Guide to Surviving Prostate Cancer by Patrick C. Walsh, Janet Farrar Worthington |
 | Biopsy Interpretation of the Prostate (Biopsy Interpretation Series) by Jonathan I Epstein, George J Netto |
 | Eat to Beat Prostate Cancer Cookbook by David Ricketts |
| © 2008 BrightSurf.com |